1. 356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab. (9th November 2020) Authors: Berinstein, Neil; Bence-Bruckler, Isabelle; Forward, Nick; Laneuville, Pierre; Mangel, Joy; Stewart, Douglas; Amitai, Irina; Klein, Gail; Pennell, Nancy; Rashedi, Iran; Roos, Kim; Bramhecha, Yogesh; Conlon, Rebekah Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A217 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab. (9th November 2020) Authors: Berinstein, Neil; Bence-Bruckler, Isabelle; Forward, Nick; Laneuville, Pierre; Mangel, Joy; Stewart, Douglas; Amitai, Irina; Klein, Gail; Pennell, Nancy; Rashedi, Iran; Roos, Kim; Bramhecha, Yogesh; Conlon, Rebekah Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A381 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Concise Review: TLR Pathway-miRNA Interplay in Mesenchymal Stromal Cells: Regulatory Roles and Therapeutic Directions. (13th October 2018) Authors: Abdi, Jahangir; Rashedi, Iran; Keating, Armand Journal: Stem cells Issue: Volume 36:Number 11(2018) Page Start: 1655 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Concise Review: TLR Pathway‐miRNA Interplay in Mesenchymal Stromal Cells: Regulatory Roles and Therapeutic Directions. (13th October 2018) Authors: Abdi, Jahangir; Rashedi, Iran; Keating, Armand Journal: Stem cells Issue: Volume 36:Number 11(2018) Page Start: 1655 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia. (December 2021) Authors: Chow, Signy; Tang, Kenny; Al-Abri, Mahmood; Hall, Victoria; Tremblay-Lemay, Rosemarie; Rashedi, Iran; Tsui, Hubert; Chan, Steven M. Journal: Leukemia research Issue: Volume 111(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. TLR3 or TLR4 Activation Enhances Mesenchymal Stromal Cell-Mediated Treg Induction via Notch Signaling. (20th September 2016) Authors: Rashedi, Iran; Gómez-Aristizábal, Alejandro; Wang, Xing-Hua; Viswanathan, Sowmya; Keating, Armand Journal: Stem cells Issue: Volume 35:Number 1(2017:Jan.) Page Start: 265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. TLR3 or TLR4 Activation Enhances Mesenchymal Stromal Cell‐Mediated Treg Induction via Notch Signaling. (20th September 2016) Authors: Rashedi, Iran; Gómez‐Aristizábal, Alejandro; Wang, Xing‐Hua; Viswanathan, Sowmya; Keating, Armand Journal: Stem cells Issue: Volume 35:Number 1(2017:Jan.) Page Start: 265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗